Stockreport

4DMT Reports Full Year 2023 Financial Results and Operational Highlights

4D Molecular Therapeutics, Inc.  (FDMT) 
PDF Presented positive interim data from randomized Dose Expansion cohort of the Phase 2 PRISM study evaluating 4D-150 in wet AMD patients with severe disease activity and h [Read more]